Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches

Dongiovanni, Paola; Paolini, Erika; Corsini, Alberto; Sirtori, Cesare R.; Ruscica, Massimiliano

doi:10.1111/eci.13519

Cited by 38 publications

(40 citation statements)

References 243 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These rates could be due to the inclusion of metabolic dysfunction criteria, which are associated with increased CVD rates, in the definition. 64 NAFLD has also been reported to be associated with cardiac arrhythmias, including atrial fibrillation (AF), prolongation of the corrected QT interval (QTc), some cardiac conduction defects, cardiac autonomic dysfunction, and sudden cardiac death. 65,66 NAFLD doubles the risk of AF (OR: 2.07; 95% CI: 1.38-3.10) independent of the traditional risk factors for AF.…”

Section: Cardiovascular Diseases (Cvds)mentioning

confidence: 99%

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Kaya¹,

Yılmaz²

2021

J Clin Transl Hepatol

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes mellitus, metabolic syndrome, cardiovascular diseases, chronic kidney disease, extrahepatic malignancies, cognitive disorders, and polycystic ovarian syndrome. Among NAFLD patients, the most common mortality etiology is cardiovascular disorders, followed by extrahepatic malignancies, diabetes mellitus, and liver-related complications. Furthermore, the severity of extrahepatic diseases is parallel to the severity of NAFLD. In clinical practice, awareness of the associations of concomitant diseases is of major importance for initiating prompt and timely screening and multidisciplinary management of the disease spectrum. In 2020, a consensus from 22 countries redefined the disease as metabolic (dysfunction)-associated fatty liver disease (MAFLD), which resulted in the redefinition of the corresponding population. Although the patients diagnosed with MAFLD and NAFLD mostly overlap, the MAFLD and NAFLD populations are not identical. In this review, we compared the associations of key extrahepatic diseases between NAFLD and MAFLD.

show abstract

Section: Cardiovascular Diseases (Cvds)mentioning

confidence: 99%

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Kaya¹,

Yılmaz²

2021

J Clin Transl Hepatol

View full text Add to dashboard Cite

show abstract

“…Результати епідеміологічних досліджень свідчать про збільшення виявлення НАЖХП у пацієнтів з інсулінорезистентністю [15,19], тому НАЖХП вважають печінковою складовою маніфестації метаболічного синдрому [12]. Жирова інфільтрація печінки виявляється у 90% пацієнтів з кардіоваску-лярною патологією [3,7,13]. НАЖХП негативно впливає на перебіг ХКС, збільшує кількість ускладнень та летальних наслідків незалежно від інших проявів метаболічного синдрому [22].…”

Section: вступunclassified

Predictor value of neurohumoral disorders in patients with chronic coronary syndrome with concomitant non-alcoholic fat disease

Mykhailovska¹,

Miniailenko²,

Lisova³

et al. 2021

Rep. of Vinnytsia Nation. Med. Univ.

View full text Add to dashboard Cite

Annotation. Today it is important to study the clinical and prognostic role of neurohumoral disorders in patients with stable forms of chronic coronary syndrome (CCS) and concomitant liver pathology. The aim of the study: to investigate the levels of markers of insulin, adipokine balance, systemic inflammation and endothelial dysfunction and their predictor value for the presence of non-alcoholic fatty liver disease (NAFLD) in patients with CCS. The prospective monocenter double open study in parallel groups involved 120 patients with CCS: stable angina pectoris II-III functional class aged 60.0 (55.0; 64.0) years, of whom 67 (55%) men and 53 (45 %) women. The control selected group included 30 healthy individuals aged 59.0 (58.0; 66.0) years, including 14 (46%) men and 16 (54%) women. Determination of the serum concentration of biomarkers (adiponectin, resistin, insulin, asymmetric dimethylarginine (ADMA), C-reactive protein) was performed using enzyme-linked immunosorbent assay. Statistical data processing was performed using the license program package “Statistica 13.0” (StatSoftInc, USA, № JPZ8041382130ARCN10-J). The hypothesis about the normality of the distribution of the studied indicators was tested using the Shapiro-Wilk test. Quantitative traits were presented as M ± m or Me (Q25; Q75), depending on the type of distribution. Significance of differences was assessed using Student's t-test (for normal distribution) or Mann-Whitney U-test for independent samples (for distribution other than normal). In order to establish the threshold values of biomarkers for predicting the presence of NAFLD ROC analysis was used. It was found that in patients with CCS with concomitant NAFLD, compared with patients with CCS without liver pathology, there is a significant (p <0,05) increase in insulin levels, HOMA index, resistin, ADMA, RF-C-reactive protein and a decrease in adiponectin concentration. According to the results of ROC analysis, it was found that ADMA (Se = 80.0; Sp = 82.9; AUC = 0.91) had a high sensitivity, the optimal ratio of sensitivity and specificity for the diagnosis of NAFLD among all studied biomarkers. Other biomarkers (HOMA index, adiponectin, resistin, adiponectin/resistin ratio) also had an AUC greater than 0.8, but smaller sensitivity/specificity ratio. Thus, in patients with CCS associated with NAFLD, compared with patients without NAFLD, an imbalance of adipocytokines on the background of insulin resistance, systemic inflammation and endothelial dysfunction is observed. Asymmetric dimethylarginine has the highest sensitivity, the optimal ratio of sensitivity and specificity for the diagnosis of NAFLD in patients with coronary artery disease.

show abstract

“…The prevalence of MAFLD among obese adults worldwide is 50.7%, with 95% CI 46.9–54.4 [ 3 ], relatively higher in men (59.0%, 95% CI 52.0–65.6) than women (47.5%, 95% CI 40.7–54.5). NAFLD is tightly associated with obesity, diabetes, and metabolic syndromes [ 4 , 5 ]. A survey study showed that over the past three decades, NAFLD is the only consistently increasing liver disease in the United States, accompanying the increase in obesity and type 2 diabetes mellitus (T2DM) [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

“…NAFLD is tightly associated with obesity, diabetes, and metabolic syndromes [ 4 , 5 ]. A survey study showed that over the past three decades, NAFLD is the only consistently increasing liver disease in the United States, accompanying the increase in obesity and type 2 diabetes mellitus (T2DM) [ 5 ]. In addition to Western countries, the prevalence of NAFLD also increases in the past two decades in Asian countries, due to the sedentary lifestyle, overnutrition, obesity, and T2DM [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Current Options and Future Directions for NAFLD and NASH Treatment

Zhang

Yang

2021

IJMS

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of nonalcoholic steatohepatitis (NASH). Although there are many undergoing clinical trials for NAFLD treatment, there is no currently approved treatment. NAFLD accounts as a major causing factor for the development of hepatocellular carcinoma (HCC), and its incidence rises accompanying the prevalence of obesity and diabetes. Reprogramming of antidiabetic and anti-obesity medicine is a major treatment option for NAFLD and NASH. Liver inflammation and cellular death, with or without fibrosis account for the progression of NAFLD to NASH. Therefore, molecules and signaling pathways involved in hepatic inflammation, fibrosis, and cell death are critically important targets for the therapy of NAFLD and NASH. In addition, the avoidance of aberrant infiltration of inflammatory cytokines by treating with CCR antagonists also provides a therapeutic option. Currently, there is an increasing number of pre-clinical and clinical trials undergoing to evaluate the effects of antidiabetic and anti-obesity drugs, antibiotics, pan-caspase inhibitors, CCR2/5 antagonists, and others on NAFLD, NASH, and liver fibrosis. Non-invasive serum diagnostic markers are developed for fulfilling the need of diagnostic testing in a large amount of NAFLD cases. Overall, a better understanding of the underlying mechanism of the pathogenesis of NAFLD is helpful to choose an optimized treatment.

show abstract

Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches

Cited by 38 publications

References 243 publications

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Predictor value of neurohumoral disorders in patients with chronic coronary syndrome with concomitant non-alcoholic fat disease

Current Options and Future Directions for NAFLD and NASH Treatment

Contact Info

Product

Resources

About